Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Need to improve availability of "access" group antibiotics and reduce the use of "watch" group antibiotics in India for optimum use of antibiotics to contain antimicrobial resistance.

Gandra S, Kotwani A.

J Pharm Policy Pract. 2019 Jul 17;12:20. doi: 10.1186/s40545-019-0182-1. eCollection 2019. No abstract available.

2.

Quantifying uncertainty about future antimicrobial resistance: Comparing structured expert judgment and statistical forecasting methods.

Colson AR, Megiddo I, Alvarez-Uria G, Gandra S, Bedford T, Morton A, Cooke RM, Laxminarayan R.

PLoS One. 2019 Jul 5;14(7):e0219190. doi: 10.1371/journal.pone.0219190. eCollection 2019.

3.

Antibiotic resistance, stewardship, and consumption - Authors' reply.

Collignon P, Beggs JJ, Walsh TR, Gandra S, Laxminarayan R.

Lancet Planet Health. 2019 Feb;3(2):e68. doi: 10.1016/S2542-5196(18)30263-8. No abstract available. Erratum in: Lancet Planet Health. 2019 Jul;3(7):e294.

4.

Reply to Chopra and Rizvi.

Gandra S, Arora A, Laxminarayan R, Klein EY.

Clin Infect Dis. 2019 Sep 13;69(7):1265-1266. doi: 10.1093/cid/ciz128. No abstract available.

PMID:
30753356
5.

Is the efficacy of antibiotic prophylaxis for surgical procedures decreasing? Systematic review and meta-analysis of randomized control trials.

Gandra S, Trett A, Alvarez-Uria G, Solomkin JS, Laxminarayan R.

Infect Control Hosp Epidemiol. 2019 Feb;40(2):133-141. doi: 10.1017/ice.2018.295. Epub 2018 Nov 12.

PMID:
30417800
6.

The mortality burden of multidrug-resistant pathogens in India: a retrospective observational study.

Gandra S, Tseng KK, Arora A, Bhowmik B, Robinson ML, Panigrahi B, Laxminarayan R, Klein EY.

Clin Infect Dis. 2018 Nov 8. doi: 10.1093/cid/ciy955. [Epub ahead of print]

7.

Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis.

Collignon P, Beggs JJ, Walsh TR, Gandra S, Laxminarayan R.

Lancet Planet Health. 2018 Sep;2(9):e398-e405. doi: 10.1016/S2542-5196(18)30186-4.

8.

Impact of elimination of contact precautions on noninfectious adverse events among MRSA and VRE patients.

Gandra S, Barysauskas CM, Mack DA, Barton B, Finberg R, Ellison RT.

Infect Control Hosp Epidemiol. 2018 Oct;39(10):1272-1273. doi: 10.1017/ice.2018.204. Epub 2018 Aug 31. No abstract available.

PMID:
30168402
9.

Developing core elements and checklist items for global hospital antimicrobial stewardship programmes: a consensus approach.

Pulcini C, Binda F, Lamkang AS, Trett A, Charani E, Goff DA, Harbarth S, Hinrichsen SL, Levy-Hara G, Mendelson M, Nathwani D, Gunturu R, Singh S, Srinivasan A, Thamlikitkul V, Thursky K, Vlieghe E, Wertheim H, Zeng M, Gandra S, Laxminarayan R.

Clin Microbiol Infect. 2019 Jan;25(1):20-25. doi: 10.1016/j.cmi.2018.03.033. Epub 2018 Apr 3.

PMID:
29625170
10.

Point prevalence surveys of antimicrobial use among eight neonatal intensive care units in India: 2016.

Gandra S, Alvarez-Uria G, Murki S, Singh SK, Kanithi R, Jinka DR, Chikkappa AK, Subramanian S, Sharma A, Dharmapalan D, Kandraju H, Vasudevan AK, Tunga O, Akula A, Hsia Y, Sharland M, Laxminarayan R.

Int J Infect Dis. 2018 Jun;71:20-24. doi: 10.1016/j.ijid.2018.03.017. Epub 2018 Mar 30.

11.

Global increase and geographic convergence in antibiotic consumption between 2000 and 2015.

Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, Goossens H, Laxminarayan R.

Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470. doi: 10.1073/pnas.1717295115. Epub 2018 Mar 26.

12.

Acinetobacter baumannii Resistance Trends in Children in the United States, 1999-2012.

Logan LK, Gandra S, Trett A, Weinstein RA, Laxminarayan R.

J Pediatric Infect Dis Soc. 2019 May 11;8(2):136-142. doi: 10.1093/jpids/piy018.

13.

Global forecast of antimicrobial resistance in invasive isolates of Escherichia coli and Klebsiella pneumoniae.

Alvarez-Uria G, Gandra S, Mandal S, Laxminarayan R.

Int J Infect Dis. 2018 Mar;68:50-53. doi: 10.1016/j.ijid.2018.01.011. Epub 2018 Feb 2.

14.

Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe.

Sharland M, Pulcini C, Harbarth S, Zeng M, Gandra S, Mathur S, Magrini N; 21st WHO Expert Committee on Selection and Use of Essential Medicines.

Lancet Infect Dis. 2018 Jan;18(1):18-20. doi: 10.1016/S1473-3099(17)30724-7. Epub 2017 Dec 20. No abstract available.

PMID:
29303731
15.

Impact of Antibiotic Policy on Antibiotic Consumption in a Neonatal Intensive Care Unit in India.

Jinka DR, Gandra S, Alvarez-Uria G, Torre N, Tadepalli D, Nayakanti RR.

Indian Pediatr. 2017 Sep 15;54(9):739-741.

PMID:
28984251
16.

Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.

Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG.

J Am Heart Assoc. 2017 Oct 2;6(10). pii: e005367. doi: 10.1161/JAHA.116.005367. Review.

17.

Point Prevalence Surveys of Antimicrobial Use among Hospitalized Children in Six Hospitals in India in 2016.

Gandra S, Singh SK, Jinka DR, Kanithi R, Chikkappa AK, Sharma A, Dharmapalan D, Vasudevan AK, Tunga O, Akula A, Garg G, Hsia Y, Murki S, Alvarez-Uria G, Sharland M, Laxminarayan R.

Antibiotics (Basel). 2017 Sep 13;6(3). pii: E19. doi: 10.3390/antibiotics6030019.

18.

Differences in utility elicitation methods in cardiovascular disease: a systematic review.

Blieden Betts M, Gandra SR, Cheng LI, Szatkowski A, Toth PP.

J Med Econ. 2018 Jan;21(1):74-84. doi: 10.1080/13696998.2017.1379410. Epub 2017 Oct 10. Review.

PMID:
28899233
19.

Clinical outcome of dual colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India.

Kaur A, Gandra S, Gupta P, Mehta Y, Laxminarayan R, Sengupta S.

Am J Infect Control. 2017 Nov 1;45(11):1289-1291. doi: 10.1016/j.ajic.2017.06.028. Epub 2017 Aug 12.

PMID:
28807425
20.

Is Antimicrobial Resistance a Bigger Problem in Tertiary Care Hospitals Than in Small Community Hospitals in the United States?

Gandra S, Trett A, Klein EY, Laxminarayan R.

Clin Infect Dis. 2017 Sep 1;65(5):860-863. doi: 10.1093/cid/cix413.

PMID:
28472253
21.

Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries.

Rosenson RS, Gandra SR, McKendrick J, Dent R, Wieffer H, Cheng LI, Catapano AL, Oh P, Kees Hovingh G, Stroes ES.

Cardiovasc Drugs Ther. 2017 Apr;31(2):187-195. doi: 10.1007/s10557-017-6727-0.

22.

Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.

Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F, Masana L, Bayes-Genis A, Hout BV.

Clin Ther. 2017 Apr;39(4):771-786.e3. doi: 10.1016/j.clinthera.2017.02.011. Epub 2017 Mar 31.

PMID:
28366593
23.

Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study.

Punekar RS, Fox KM, Paoli CJ, Richhariya A, Cziraky MJ, Gandra SR, Toth PP.

Curr Med Res Opin. 2017 May;33(5):869-876. doi: 10.1080/03007995.2017.1292898. Epub 2017 Mar 9.

PMID:
28276256
24.

A systematic review to assess adherence and persistence with statins.

Deshpande S, Quek RG, Forbes CA, de Kock S, Kleijnen J, Gandra SR, Simpson RJ Jr.

Curr Med Res Opin. 2017 Apr;33(4):769-778. doi: 10.1080/03007995.2017.1281109. Epub 2017 Jan 20. Review.

PMID:
28076703
25.

Longitudinal treatment patterns among US patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia initiating lipid-lowering pharmacotherapy.

Burke JP, Simpson RJ Jr, Paoli CJ, McPheeters JT, Gandra SR.

J Clin Lipidol. 2016 Nov - Dec;10(6):1470-1480.e3. doi: 10.1016/j.jacl.2016.09.002. Epub 2016 Sep 13.

PMID:
27919365
26.

Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa in Children, United States, 1999-2012.

Logan LK, Gandra S, Mandal S, Klein EY, Levinson J, Weinstein RA, Laxminarayan R; Prevention Epicenters Program, US Centers for Disease Control and Prevention.

J Pediatric Infect Dis Soc. 2017 Nov 24;6(4):352-359. doi: 10.1093/jpids/piw064.

27.

Productivity losses associated with cardiovascular disease: a systematic review.

Gordois AL, Toth PP, Quek RG, Proudfoot EM, Paoli CJ, Gandra SR.

Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):759-769. Epub 2016 Nov 21. Review.

PMID:
27831848
28.

Poverty and prevalence of antimicrobial resistance in invasive isolates.

Alvarez-Uria G, Gandra S, Laxminarayan R.

Int J Infect Dis. 2016 Nov;52:59-61. doi: 10.1016/j.ijid.2016.09.026. Epub 2016 Oct 4.

29.

A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.

Wei CY, Quek RGW, Villa G, Gandra SR, Forbes CA, Ryder S, Armstrong N, Deshpande S, Duffy S, Kleijnen J, Lindgren P.

Pharmacoeconomics. 2017 Mar;35(3):297-318. doi: 10.1007/s40273-016-0464-2. Review.

PMID:
27785772
30.

Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden.

Banefelt J, Hallberg S, Fox KM, Mesterton J, Paoli CJ, Johansson G, Levin LÅ, Sobocki P, Gandra SR.

Eur J Health Econ. 2016 Dec;17(9):1117-1124. Epub 2015 Nov 25.

31.

Patient-level costs of major cardiovascular conditions: a review of the international literature.

Nicholson G, Gandra SR, Halbert RJ, Richhariya A, Nordyke RJ.

Clinicoecon Outcomes Res. 2016 Sep 21;8:495-506. eCollection 2016. Review.

32.

Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008-2014.

Gandra S, Mojica N, Klein EY, Ashok A, Nerurkar V, Kumari M, Ramesh U, Dey S, Vadwai V, Das BR, Laxminarayan R.

Int J Infect Dis. 2016 Sep;50:75-82. doi: 10.1016/j.ijid.2016.08.002. Epub 2016 Aug 10.

33.

Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia.

Wang A, Richhariya A, Gandra SR, Calimlim B, Kim L, Quek RG, Nordyke RJ, Toth PP.

J Am Heart Assoc. 2016 Jul 6;5(7). pii: e003294. doi: 10.1161/JAHA.116.003294. Review.

34.

A role for private sector laboratories in public health surveillance of antimicrobial resistance.

Gandra S, Merchant AT, Laxminarayan R.

Future Microbiol. 2016 Jun;11:709-12. doi: 10.2217/fmb.16.17. Epub 2016 May 18. No abstract available.

35.

The relationship between Lp(a) and CVD outcomes: a systematic review.

Forbes CA, Quek RG, Deshpande S, Worthy G, Wolff R, Stirk L, Kleijnen J, Gandra SR, Djedjos S, Wong ND.

Lipids Health Dis. 2016 May 17;15:95. doi: 10.1186/s12944-016-0258-8. Review.

36.

Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Low-density Lipoprotein Cholesterol Levels in Older High-risk Adults.

Zhao Y, Delaney JA, Quek RG, Gardin JM, Hirsch CH, Gandra SR, Wong ND.

Clin Cardiol. 2016 Jul;39(7):413-20. doi: 10.1002/clc.22546. Epub 2016 May 13.

37.

Chronic Activation of γ2 AMPK Induces Obesity and Reduces β Cell Function.

Yavari A, Stocker CJ, Ghaffari S, Wargent ET, Steeples V, Czibik G, Pinter K, Bellahcene M, Woods A, Martínez de Morentin PB, Cansell C, Lam BY, Chuster A, Petkevicius K, Nguyen-Tu MS, Martinez-Sanchez A, Pullen TJ, Oliver PL, Stockenhuber A, Nguyen C, Lazdam M, O'Dowd JF, Harikumar P, Tóth M, Beall C, Kyriakou T, Parnis J, Sarma D, Katritsis G, Wortmann DD, Harper AR, Brown LA, Willows R, Gandra S, Poncio V, de Oliveira Figueiredo MJ, Qi NR, Peirson SN, McCrimmon RJ, Gereben B, Tretter L, Fekete C, Redwood C, Yeo GS, Heisler LK, Rutter GA, Smith MA, Withers DJ, Carling D, Sternick EB, Arch JR, Cawthorne MA, Watkins H, Ashrafian H.

Cell Metab. 2016 May 10;23(5):821-36. doi: 10.1016/j.cmet.2016.04.003. Epub 2016 Apr 28.

38.

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.

Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, van Hout B.

Clin Cardiol. 2016 Jun;39(6):313-20. doi: 10.1002/clc.22535. Epub 2016 Apr 19. Erratum in: Clin Cardiol. 2016 Oct;39(10 ):621.

39.

Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review.

Forbes C, Quek RG, Deshpande S, Worthy G, Ross J, Kleijnen J, Gandra SR, Kassahun H, Wong ND, Nicholls SJ.

Curr Med Res Opin. 2016 Jun;32(6):1143-50. doi: 10.1185/03007995.2016.1162775. Epub 2016 Mar 17. Review.

PMID:
26949994
40.

Faropenem Consumption is Increasing in India.

Gandra S, Klein EY, Pant S, Malhotra-Kumar S, Laxminarayan R.

Clin Infect Dis. 2016 Apr 15;62(8):1050-2. doi: 10.1093/cid/ciw055. Epub 2016 Feb 7. No abstract available. Erratum in: Clin Infect Dis. 2017 Aug 1;65(3):533.

PMID:
26908807
41.

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States.

Unni SK, Quek RG, Biskupiak J, Lee VC, Ye X, Gandra SR.

J Clin Lipidol. 2016 Jan-Feb;10(1):63-71.e1-3. doi: 10.1016/j.jacl.2015.09.008. Epub 2015 Sep 25.

42.

Design and optimization of disintegrating pellets of MCC by non-aqueous extrusion process using statistical tools.

Gurram RK, Gandra S, Shastri NR.

Eur J Pharm Sci. 2016 Mar 10;84:146-56. doi: 10.1016/j.ejps.2016.01.021. Epub 2016 Jan 23.

PMID:
26812204
43.

Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.

Hallberg S, Banefelt J, Fox KM, Mesterton J, Johansson G, Levin LÅ, Sobocki P, Gandra SR.

Int J Clin Pract. 2016 Mar;70(3):222-8. doi: 10.1111/ijcp.12769. Epub 2016 Jan 22.

44.

Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study.

Fox KM, Wang L, Gandra SR, Quek RGW, Li L, Baser O.

BMC Cardiovasc Disord. 2016 Jan 14;16:13. doi: 10.1186/s12872-016-0190-x.

45.

Erratum to: 'Costs of treating cardiovascular events in Germany: a systematic literature review'.

Schmid T, Xu W, Gandra SR, Michailov GV.

Health Econ Rev. 2016 Dec;6(1):1. doi: 10.1186/s13561-016-0080-z. No abstract available.

46.

A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event.

Quek RGW, Fox KM, Wang L, Li L, Gandra SR, Wong ND.

Am J Cardiol. 2016 Feb 15;117(4):495-500. doi: 10.1016/j.amjcard.2015.11.035. Epub 2015 Dec 2.

47.

Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey.

Hovingh GK, Gandra SR, McKendrick J, Dent R, Wieffer H, Catapano AL, Oh P, Rosenson RS, Stroes ES.

Atherosclerosis. 2016 Feb;245:111-7. doi: 10.1016/j.atherosclerosis.2015.12.015. Epub 2015 Dec 11.

PMID:
26717273
48.

A Retrospective Study to Examine Healthcare Costs Related to Cardiovascular Events in Individuals with Hyperlipidemia.

Henk HJ, Paoli CJ, Gandra SR.

Adv Ther. 2015 Nov;32(11):1104-16. doi: 10.1007/s12325-015-0264-7. Epub 2015 Nov 19.

49.

Reversion From Methicillin Susceptibility to Methicillin Resistance in Staphylococcus aureus During Treatment of Bacteremia.

Proulx MK, Palace SG, Gandra S, Torres B, Weir S, Stiles T, Ellison RT 3rd, Goguen JD.

J Infect Dis. 2016 Mar 15;213(6):1041-8. doi: 10.1093/infdis/jiv512. Epub 2015 Oct 26.

50.

Carbapenem-Resistant Enterobacteriaceae in Children, United States, 1999-2012.

Logan LK, Renschler JP, Gandra S, Weinstein RA, Laxminarayan R; Centers for Disease Control; Prevention Epicenters Program.

Emerg Infect Dis. 2015 Nov;21(11):2014-21. doi: 10.3201/eid2111.150548.

Supplemental Content

Loading ...
Support Center